These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29604203)

  • 1. The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer.
    Di Meo A; Wang C; Cheng Y; Diamandis EP; Yousef GM
    Biol Chem; 2018 Sep; 399(9):973-982. PubMed ID: 29604203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there.
    Pasic MD; Olkhov E; Bapat B; Yousef GM
    Biol Chem; 2012 Apr; 393(5):319-30. PubMed ID: 22505515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer.
    White NM; Youssef YM; Fendler A; Stephan C; Jung K; Yousef GM
    Biol Chem; 2012 Apr; 393(5):379-89. PubMed ID: 22505520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNAs: a new frontier in kallikrein research.
    Yousef GM
    Biol Chem; 2008 Jun; 389(6):689-94. PubMed ID: 18627305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs.
    White NM; Bui A; Mejia-Guerrero S; Chao J; Soosaipillai A; Youssef Y; Mankaruos M; Honey RJ; Stewart R; Pace KT; Sugar L; Diamandis EP; Doré J; Yousef GM
    Biol Chem; 2010 Apr; 391(4):411-23. PubMed ID: 20180642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.
    White NM; Chow TF; Mejia-Guerrero S; Diamandis M; Rofael Y; Faragalla H; Mankaruous M; Gabril M; Girgis A; Yousef GM
    Br J Cancer; 2010 Apr; 102(8):1244-53. PubMed ID: 20354523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kallikreins are involved in an miRNA network that contributes to prostate cancer progression.
    Samaan S; Lichner Z; Ding Q; Saleh C; Samuel J; Streutker C; Yousef GM
    Biol Chem; 2014 Sep; 395(9):991-1001. PubMed ID: 25153383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kallikreins as microRNA targets: an in silico and experimental-based analysis.
    Chow TF; Crow M; Earle T; El-Said H; Diamandis EP; Yousef GM
    Biol Chem; 2008 Jun; 389(6):731-8. PubMed ID: 18627289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
    Avgeris M; Scorilas A
    Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
    Figueroa CD; Molina L; Bhoola KD; Ehrenfeld P
    Biol Chem; 2018 Sep; 399(9):937-957. PubMed ID: 29885274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kallikrein-related peptidases and associated microRNAs as promising prognostic biomarkers in gastrointestinal malignancies.
    Adamopoulos PG; Tsiakanikas P; Scorilas A
    Biol Chem; 2018 Jul; 399(8):821-836. PubMed ID: 29883317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers.
    Kontos CK; Scorilas A
    Clin Chem Lab Med; 2012 Nov; 50(11):1877-91. PubMed ID: 23093268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
    Scorilas A; Mavridis K
    Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epigenetic basis for the aberrant expression of kallikreins in human cancers.
    Pampalakis G; Diamandis EP; Sotiropoulou G
    Biol Chem; 2006 Jun; 387(6):795-9. PubMed ID: 16800742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional roles of human kallikrein-related peptidases.
    Sotiropoulou G; Pampalakis G; Diamandis EP
    J Biol Chem; 2009 Nov; 284(48):32989-94. PubMed ID: 19819870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kallikrein-related peptidases (KLKs) and the hallmarks of cancer.
    Filippou PS; Karagiannis GS; Musrap N; Diamandis EP
    Crit Rev Clin Lab Sci; 2016 Aug; 53(4):277-91. PubMed ID: 26886390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers.
    Emami N; Diamandis EP
    Clin Chem; 2008 Oct; 54(10):1600-7. PubMed ID: 18687738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies.
    Avgeris M; Mavridis K; Scorilas A
    Biol Chem; 2010 May; 391(5):505-11. PubMed ID: 20302518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies.
    Dorn J; Bayani J; Yousef GM; Yang F; Magdolen V; Kiechle M; Diamandis EP; Schmitt M
    Thromb Haemost; 2013 Sep; 110(3):408-22. PubMed ID: 23765253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interdependence of kallikrein-related peptidases in proteolytic networks.
    Beaufort N; Plaza K; Utzschneider D; Schwarz A; Burkhart JM; Creutzburg S; Debela M; Schmitt M; Ries C; Magdolen V
    Biol Chem; 2010 May; 391(5):581-7. PubMed ID: 20302517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.